Pharmaceutical supply chain risk assessment in Iran using analytic hierarchy process (AHP) and simple additive weighting (SAW) methods

ObjectivesPharmaceutical supply chain is a significant component of the health system in supplying medicines, particularly in countries where main drugs are provided by local pharmaceutical companies. No previous studies exist assessing risks and disruptions in pharmaceutical companies while assessing the pharmaceutical supply chain. Any risks affecting the pharmaceutical companies could disrupt supply medicines and health system efficiency. The goal of this study was the risk assessment in pharmaceutical industry in Iran considering process's priority, hazard and probability of risks.MethodsThe study was carried out in 4 phases; risk identification through literature review, risk identification in Iranian pharmaceutical companies through interview with experts, risk analysis through a questionnaire and consultation with experts using group analytic hierarchy process (AHP) method and rating scale (RS) and risk evaluation of simple additive weighting (SAW) method.ResultsIn total, 86 main risks were identified in the pharmaceutical supply chain with perspective of pharmaceutical companies classified in 11 classes. The majority of risks described in this study were related to the financial and economic category. Also financial management was found to be the most important factor for consideration.ConclusionAlthough pharmaceutical industry and supply chain were affected by current political conditions in Iran during the study time, but half of total risks in the pharmaceutical supply chain were found to be internal risks which could be fixed by companies, internally. Likewise, political status and related risks forced companies to focus more on financial and supply management resulting in less attention to quality management.

[1]  J. R. Carter,et al.  An analysis of supply risk assessment techniques , 2004 .

[2]  Jennifer Blackhurst,et al.  The Severity of Supply Chain Disruptions: Design Characteristics and Mitigation Capabilities , 2007, Decis. Sci..

[3]  Iwan Vanany,et al.  Supply Chain Risk Management: Literature Review and Future Research , 2007, Int. J. Inf. Syst. Supply Chain Manag..

[4]  M. Bohanec,et al.  The Analytic Hierarchy Process , 2004 .

[5]  Joel Lexchin,et al.  The pharmaceutical industry as a medicines provider , 2002, The Lancet.

[6]  Alireza Alinezhad,et al.  Sensitivity Analysis of Simple Additive Weighting Method (SAW): The Results of Change in the Weight of One Attribute on the Final Ranking of Alternatives , 2009 .

[7]  Liz Breen,et al.  A Preliminary Examination of Risk in the Pharmaceutical Supply Chain (PSC) in the National Health Service (NHS) , 2008 .

[8]  Ching-Fu Chen.  Applying the Analytical Hierarchy Process (AHP) Approach to Convention Site Selection , 2006 .

[9]  José María Moreno-Jiménez,et al.  Consensus Building in AHP-Group Decision Making: A Bayesian Approach , 2010, Oper. Res..

[10]  H. Hogerzeil.  Essential medicines and human rights: what can they learn from each other? , 2006, Bulletin of the World Health Organization.

[11]  Saul I. Gass,et al.  Encyclopedia of Operations Research and Management Science , 1997 .

[12]  Chris I. Enyinda,et al.  An empirical analysis of risk mitigation in the pharmaceutical industry supply chain: A developing-country perspective , 2010 .

[13]  Nilay Shah,et al.  Pharmaceutical supply chains: key issues and strategies for optimisation , 2004, Comput. Chem. Eng..

[14]  R. Dinarvand.  A New Pharmaceutical Environment in Iran: Marketing Impacts , 2010 .

[15]  Jamal F. Al‐Bahar,et al.  Systematic Risk Management Approach for Construction Projects , 1990 .

[16]  R. Habashy.  Quality risk management methodology in pharmaceutical industry (ICH Q9/FDA/WHO) , 2014 .

[17]  Thomas L. Saaty,et al.  How to Make a Decision: The Analytic Hierarchy Process , 1990 .

[18]  Ching-Lai Hwang,et al.  Multiple attribute decision making : an introduction , 1995 .

[19]  Germaine H. Saad,et al.  Managing Disruption Risks in Supply Chains , 2005 .

[20]  Rassoul Dinarvand,et al.  Pharmaceutical supply chain risks: a systematic review , 2013, DARU Journal of Pharmaceutical Sciences.

[21]  D. Andrich.  Application of a Psychometric Rating Model to Ordered Categories Which Are Scored with Successive Integers , 1978 .

[22]  Lilli Møller Andersen,et al.  Quality Risk Management , 2021, Handbook of Pharmaceutical Manufacturing Formulations, Second Edition.

[23]  Programmierbarer Thermoblock,et al.  From industry , 1991 .

[24]  Uta Jüttner.  Supply chain risk management: Understanding the business requirements from a practitioner perspective , 2005 .

[25]  R. Dinarvand.  New national drug policy in Iran leading to expanded pharmaceutical market and extended access of public to medicines. , 2009 .

[26]  M. T. Escobar,et al.  Aggregation of Individual Preference Structures in Ahp-Group Decision Making , 2007 .

[27]  M. Christopher,et al.  Demand chain management-integrating marketing and supply chain management , 2007 .

[28]  Iftekhar A. Karimi,et al.  Supply chain redesign and new process introduction in multipurpose plants , 2010 .

[29]  M. Abdollahi,et al.  Efficacies of Regulatory Policies to Control Massive Use of Diphenoxylate , 2012 .

[30]  Nilay Shah,et al.  Process industry supply chains: Advances and challenges , 2005, Comput. Chem. Eng..

[31]  Gholamhossein Mehralian,et al.  Developing a Suitable Model for Supplier Selection Based on Supply Chain Risks: An Empirical Study from Iranian Pharmaceutical Companies , 2012, Iranian journal of pharmaceutical research : IJPR.

[32]  Andreas Norrman,et al.  Categorization of supply chain risk and risk management , 2004 .